RESUMO
Objectives: We determined the incidence of post-COVID-19 syndrome and its association with COVID-19 severity among patients discharged in a tertiary private hospital. Methods: This single-center prospective cohort study included admitted patients 18 years old and older, diagnosed with COVID-19, discharged recovered, and interviewed at least 6 months from onset of COVID-19. Incidence of post-COVID-19 syndrome obtained and its association with COVID-19 severity was analyzed. Results: Among the 280 patients included in the study, 71.43% were diagnosed with post-COVID-19 syndrome, with higher proportion in men (53%). The median age was 50 (18-92) years old. All severe COVID-19 cases (21%) had post-COVID-19 syndrome. The leading comorbidities were hypertension (25%) and diabetes mellitus (10%). Top three symptoms were shortness of breath (42%), fatigue (38%), and body malaise (36%). Moderate cases had about five times higher odds of post-COVID-19 syndrome than mild cases. Severe cases had 92 times higher odds of having post-COVID-19 syndrome than mild cases. COVID-19 severity at baseline was significantly associated with post-COVID-19 syndrome. Conclusion: This study found a high incidence of post-COVID-19 syndrome with a higher proportion occurring in men. Severe cases had higher odds of having post-COVID-19 syndrome than mild cases.
RESUMO
OBJECTIVES: Colistimethate sodium (colistin) is used to treat multidrug-resistant gram negative infections. We describe the profile and outcomes of patients given colistin in a tertiary level government hospital in Manila, Philippines. METHODS: We performed a retrospective study of adult patients given intravenous colistin between January 2015 to June 2018 in the Philippine General Hospital. We defined clinical success as a composite of hemodynamic stability, quick Sequential Organ Failure Assessment (qSOFA) score, and microbiological cure. RESULTS: 250 patients were included, half (49.2%) were admitted in the ICU. Median age was 55 years. There was an increase in qSOFA, APACHE II score, and septic shock from baseline to 24 h prior to colistin use. Most patients had pneumonia (90.8%) with extensively drug-resistant Acinetobacter baumannii as the most common isolate (78.8%). Colistin was given in combination with meropenem (96.4%) for a median of 12 days. Nephrotoxicity was seen in 30.8%, with renal replacement therapy needed in 6%. Clinical success was seen in 61.2% of patients and overall mortality was 41.6%. CONCLUSION: Colistin was frequently used in combination with a carbapenem for treatment of XDR-related respiratory infections. Nephrotoxicity was a common adverse effect. Clinical success was modest and overall mortality was high.
